These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33161237)

  • 21. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer.
    Nieto Y; Nawaz S; Jones RB; Shpall EJ; Cagnoni PJ; McSweeney PA; Barón A; Razook C; Matthes S; Bearman SI
    J Clin Oncol; 2002 Feb; 20(3):707-18. PubMed ID: 11821452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local treatment in oligometastasis from breast cancer: an overview.
    Burgaleta AM; Burguete AB; Gutiérrez LR; Nuín EB; Felipe GA; de la Vega FA
    Clin Transl Oncol; 2023 Oct; 25(10):2861-2867. PubMed ID: 37106239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.
    Makhlin I; Fox K
    Curr Oncol Rep; 2020 Feb; 22(2):15. PubMed ID: 32025905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer.
    Yano T; Okamoto T; Haro A; Fukuyama S; Yoshida T; Kohno M; Maehara Y
    Lung Cancer; 2013 Dec; 82(3):431-5. PubMed ID: 24113550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ablative Therapies in Metastatic Breast Cancer: A Systematic Review.
    Kucharczyk MJ; Parpia S; Walker-Dilks C; Banfield L; Swaminath A
    Breast Cancer Res Treat; 2017 Jul; 164(1):13-25. PubMed ID: 28401364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
    Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival outcomes following aggressive treatment of oligometastatic breast cancer: a systematic review protocol.
    Coombe R; Lisy K; Campbell J; Perry G; Prasannan S
    JBI Database System Rev Implement Rep; 2017 Aug; 15(8):2013-2019. PubMed ID: 28800049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial.
    Ladbury C; Hao C; Ruel C; Liu J; Glaser S; Amini A; Wong J; Paz I; Leong L; Morgan R; Margolin K; Shibata S; Frankel P; Somlo G; Dandapani S
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.
    Schneeweiss A; Hensel M; Sinn P; Khbeis T; Haas R; Bastert G; Ho AD
    Ann Oncol; 2002 May; 13(5):679-88. PubMed ID: 12075735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer.
    Ayash LJ; Wheeler C; Fairclough D; Schwartz G; Reich E; Warren D; Schnipper L; Antman K; Frei E; Elias A
    J Clin Oncol; 1995 Aug; 13(8):2043-9. PubMed ID: 7636547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Metastatic Synovial Sarcoma: Experience of the CWS Study Group.
    Scheer M; Dantonello T; Hallmen E; Vokuhl C; Leuschner I; Sparber-Sauer M; Kazanowska B; Niggli F; Ladenstein R; Bielack SS; Klingebiel T; Koscielniak E
    Pediatr Blood Cancer; 2016 Jul; 63(7):1198-206. PubMed ID: 27003095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study.
    Ma Y; Duan F; Zhuang Y; Song C; Huang J; Xia W; Hong R; Zheng Q; Wang S; Shi Y; Xu F; Yuan Z; Bi X
    J Oncol; 2022; 2022():7839041. PubMed ID: 36245976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
    Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
    Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
    Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
    Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.